Janssen reports positive data for combination multiple myeloma therapy

Janssen has announced new clinical data that demonstrates the benefits of new combination regimens for the treatment of multiple myeloma.

The findings of two post-hoc analyses of the pivotal phase III POLLUX and CASTOR clinical studies offered evidence of the safety and efficacy of Janssen's drug Darzalex when taken in combination with lenalidomide and dexamethasone in the former study, or bortezomib and dexamethasone in the latter.

Both regimens were shown to significantly improve progression-free survival and overall response rates for previously-treated patients with multiple myeloma, regardless of their prior treatment exposure or cytogenetic risk.

Darzalex has now received regulatory approvals in the relapsed or refractory setting as both a monotherapy and in combination with two standard of care regimens.

Dr Peter Lebowitz, the oncology therapeutic area head at Janssen Research and Development, said: "We look forward to continued study of this compound to better understand its utility in various combinations and for patients across the treatment continuum."

The drug is currently being evaluated in a comprehensive clinical development programme that includes five phase III studies across a range of treatment settings in multiple myeloma, including the frontline and relapsed settings.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.